➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Last Updated: September 25, 2021

DrugPatentWatch Database Preview

Details for Patent: 6,335,369

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,335,369 protect, and when does it expire?

Patent 6,335,369 protects CARNITOR and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 6,335,369

Title:	Treating chronic uremic patients undergoing periodical dialysis
Abstract:	Chronic uremic patients undergoing periodical dialysis are treated with carnitine or one of its salts to prevent or treat carnitine deficiency in patients with end stage renal disease. An effective dose of carnitine, preferably L-carnitine fumarate, is administered preferably intravenously into the venous return line after each dialysis session.
Inventor(s):	Cavazza; Claudio (Rome, IT)
Assignee:	Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (Rome, IT)
Application Number:	09/761,639
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 6,335,369

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Leadiant Biosci Inc	CARNITOR	levocarnitine	INJECTABLE;INJECTION	020182-001	Dec 16, 1992	AP	RX	Yes	Yes	⤷ Try it Free	⤷ Try it Free				USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS	⤷ Try it Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 6,335,369

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	3050201	⤷ Try it Free
Canada	2381187	⤷ Try it Free
European Patent Office	1257266	⤷ Try it Free
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic

McKinsey

Harvard Business School

Boehringer Ingelheim

Dow

Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.